# Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

> **NCT01989546** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Advanced Ovarian Cancer
- Primary Peritoneal Cancer
- Advanced Breast Cancer
- Advanced Solid Tumors

## Interventions

- **DRUG:** BMN 673

## Key facts

- **NCT ID:** NCT01989546
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-04
- **Primary completion:** 2020-03-26
- **Final completion:** 2020-03-26
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01989546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01989546, "Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01989546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*